Effect of Type 2 Diabetes Mellitus Patient’s Serum as Preconditioning on Umbilical Cord Mesenchymal–Derived Secretome Production

• Published in: Regenerative engineering and translational medicine Vol. 8; no. 4; pp. 607 - 614
• Main Authors: Chouw, Angliana, Sartika, Cynthia Retna, Milanda, Tiana, Faried, Ahmad
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.12.2022; Springer Nature B.V
• Subjects: Biomaterials; Biomedical Engineering and Bioengineering; Chemistry and Materials Science; Cytokines; Diabetes; Diabetes mellitus; Effectiveness; Flow cytometry; Growth factors; Materials Science; Original Research; Preconditioning; Regenerative medicine; Regenerative Medicine/Tissue Engineering; Stem cells; Umbilical cord; Patient’s serum; Secretome; Type 2 Diabetes Mellitus; Preconditioned treatment; Mesenchymal stem cells
• ISSN: 2364-4133; 2364-4141
• DOI: 10.1007/s40883-022-00259-w

Purpose The trend of regenerative medicine is shifting toward the potency of Umbilical Cord Mesenchymal–derived Secretome (UC-MSCs-derived secretome) in treating many diseases such as Type 2 Diabetes Mellitus (T2DM). The UC-MSCs-derived secretome consists of wide range of biological active molecules, such as cytokines, mRNAs, and growth factors. T2DM patient’s serum is used as precondition treatment to induce the UC-MSCs secretome that could benefit in regenerative medicine. Methods In brief, UC-MSCs were cultured with T2DM patient’s serum for 24 hours and the culture media was collected. Flow cytometry was used to detect the Angiopoietin-2 (Ang-2), Hepatocytes Growth Factor (HGF), Interleukins-10 (IL-10), Stem Cell Factor (SCF), Granulocyte–Macrophage Colony-Stimulating Factor (GM-CSF), Vascular Endothelial Growth Factor (VEGF), Epidermal Growth Factor (EGF), and Fibroblast Growth Factor (FGF) in UC-MSCs-derived secretome. Results A significant increase ( p  < 0.05) was observed in all detected growth factors and cytokines in the UC-MSCs secretome, except for the IL-10 which was decreasing. Conclusion The preconditioning treatment with T2DM patient’s serum that has a chronic inflammation condition altered the expression of the growth factors and cytokine release by the UC-MSCs. However, further study to analyze the potency and efficacy of UC-MSCs-derived secretome from preconditioned with T2DM patient’s serum is needed in T2DM model. Lay Summary Umbilical Cord Mesenchymal–derived Secretome (UC-MSCs-derived secretome) has been used for treating many diseases. Up to now, there is no specific secretome to treat certain diseases. In this study, we used Type 2 Diabetes Mellitus (T2DM) patient’s serum as precondition treatment to induce the UC-MSCs secretome that could benefit in treating T2DM. However, further study to analyze the potency and efficacy of UC-MSCs-derived secretome from preconditioned with T2DM patient’s serum is needed in T2DM model.